Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Mesoblast limited save search
Single Dose of Mesoblast’s Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patients With Degenerative Disc Disease36-Month Results of Phase 3 Trial in Chronic Low Back Pain Presented at 2022 Biotech Showcase
Published: 2022-01-12 (Crawled : 06:00) - biospace.com/
MESO | $5.97 7.96% 7.37% 630K
|
Health Technology
|
| O: 6.4%
H: 0.0%
C: -3.21%
phase 3
Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Phase 3 Trial of Rexlemestrocel-L in Chronic Heart Failure
Published: 2021-11-15 (Crawled : 01:00) - globenewswire.com
MESO | $5.97 7.96% 7.37% 630K
|
Health Technology
|
| O: 7.99%
H: 0.0%
C: 0.0%
presentation heart phase 3 trial
Rexlemestrocel-L Phase 3 Trial Results in Chronic Heart Failure Selected as Late Breaking Presentation at American Heart Association Annual Meeting
Published: 2021-10-07 (Crawled : 01:00) - globenewswire.com
MESO | $5.97 7.96% 7.37% 630K
|
Health Technology
|
| O: 1.8%
H: 1.59%
C: -0.18%
presentation heart results phase 3 trial trial results
Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc Disease
Published: 2021-02-10 (Crawled : 00:00) - globenewswire.com
MESO | $5.97 7.96% 7.37% 630K
|
Health Technology
|
| O: 15.64%
H: 2.01%
C: -4.45%
disease opioid injection results phase 3 trial
Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference
Published: 2021-01-11 (Crawled : 23:00) - globenewswire.com
MESO | $5.97 7.96% 7.37% 630K
|
Health Technology
|
| O: -9.91%
H: 0.29%
C: -0.29%
results heart phase 3 trial trial results
Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure
Published: 2020-12-14 (Crawled : 23:01) - globenewswire.com
MESO | $5.97 7.96% 7.37% 630K
|
Health Technology
|
| O: -12.08%
H: 0.27%
C: -8.62%
heart results phase 3 trial topline
Data Safety Monitoring Board Recommends Continuation of Remestemcel-L Phase 3 Trial in COVID-19 Patients With Acute Respiratory Distress Syndrome
Published: 2020-09-04 (Crawled : 14:27) - globenewswire.com
MESO | $5.97 7.96% 7.37% 630K
|
Health Technology
|
| O: -0.22%
H: 0.9%
C: -6.01%
covid respiratory phase 3 trial syndros
Randomized Controlled Phase 3 Trial of Remestemcel-L for Reduced Mortality in COVID-19 Acute Respiratory Distress Syndrome Surpasses 50% Enrollment
Published: 2020-10-13 (Crawled : 14:27) - globenewswire.com
MESO | $5.97 7.96% 7.37% 630K
|
Health Technology
|
| O: -0.08%
H: 1.42%
C: 0.33%
covid respiratory phase 3 trial syndros enroll
Second Interim Analysis of Clinical Outcomes After 135 Patients Results in Recommendation to Continue Remestemcel-L Phase 3 Trial in COVID-19 ARDS
Published: 2020-11-11 (Crawled : 14:26) - globenewswire.com
MESO | $5.97 7.96% 7.37% 630K
|
Health Technology
|
| O: 3.36%
H: 0.83%
C: -1.58%
covid results phase 3 trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.